Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 526

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 526
---
 vivo).

Figure 5. Blocking VISTA with KVA12123 drives anti-tumor responses in MB49 model

In preclinical models, KVA12123 has been observed to show strong single agent tumor growth inhibition in poorly immunogenic “cold tumors” models and complementary tumor growth inhibition when dosed in combination with CPIs like PD-1 or CTLA-4 as shown in Figure 6 below. Studies in preclinical tumor models demonstrate the tumor growth inhibition of Kineta’s anti-VISTA antibody as a single agent in bladder cancer, T cell lymphoma and colon cancer models. In combination studies, Kineta’s anti-VISTA antibody acts synergistically in combination with anti-PD-1 therapy to inhibit tumor growth in preclinical colon cancer and bladder cancer models.**

<div align='center'>328</div>

#### Figure 6.KVA12123 demonstrates single agent tumor growth inhibition and in combination withPD-1in preclinical modelsSource: Kineta data329
Kineta has completed multiple, single and repeat-dose toxicology studies in non-humanprimates (“NHP”) with doses of KVA12123 up to 100 mg/kg (>100-foldsafety margin over target human exposure). KVA12123 was observed to be well-tolerated in NHP toxicology studies with no mortality, no overt clinical signs or weight loss, no treatment-related findings and no change in CRS-associatedcytokine levels (IL6 or TNFα). IL6 and TNFα are indicators of CRS. KVA12123 Competitive Differentiation The competitive landscape for VISTA blocking immunotherapies includes four primary companies (Kineta, Inc., Hummingbird Bioscience Pte. Ltd., PharmAbcine, Inc. and Sensei Biotherapeutics, Inc.) with assets in Phase 1 clinical development. Other discovery stage assets have been announced by Apexigen, Inc. and Five Prime Therapeutics (acquired by Amgen Inc.)/Bristol Myers Squibb Company (“BMS”). See Figure 7 below for more information on competitive products in development. Kineta is developing a VISTA blocking immunotherapy that is designed to be differentiated from competitive products by the following:

| • |     | Engineered IgG1 mAb that binds to a unique epitope |

| • |     | Binding at physiologic and acidic pH in the TME (See Figure 8) |

| • |     | Demonstrated single agent tumor growth inhibition as a monotherapy and in combination with PD